ArticleBlood red cells & iron2025
Effect of vitamin D and omega-3 fatty acid supplementation on anemia incidence among older adults: the VITAL trial.
Article in Blood red cells & iron, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Vitamin D and marine-derived long-chain n-3 (omega-3) fatty acids (FAs) may represent a novel intervention to prevent anemia of inflammation. We report the results of an ancillary study of the larger Vitamin D and Omega-3 Trial (VITAL), which looked at the effect of vitamin D and/or omega-3 FA supplementation on incidence of anemia in midlife and older adults. VITAL is a randomized, double-blinded, placebo-controlled trial, with a 2 × 2 factorial design. We focus on a subcohort of 839 participants without baseline anemia evaluated at the Boston Clinical and Translational Science Center. The primary end point was incidence of anemia (hemoglobin <13 g/dL for men, and <12 g/dL for women measured, at 2 years). The secondary end point was change in hemoglobin from baseline to 2 years. Incidence of anemia in our cohort was 9.3% over 2 years. Neither vitamin D nor omega-3 FAs had significant effect on anemia incidence (odds ratio [OR], 0.94 [95% confidence interval (CI), 0.59-1.51] and 1.31 [95% CI, 0.82-2.09], respectively) or change in hemoglobin from baseline to 2 years. There were no significant differences when stratified by race, sex, body mass index, or baseline vitamin D level. Omega-3 FAs had a statistically significant effect on change in hemoglobin in participants with baseline C-reactive protein >3 mg/L (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.